ArticleEpidemiology and health2017
Geographic distribution of the incidence of colorectal cancer in Iran: a population-based study.
Article in Epidemiology and health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 5 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Pooled it
- Scientometric Analysis of Articles on Spatial Epidemiology of Cancer in Iran: A Systematic Review.Iranian journal of medical sciences · 2023Pooled it
- A systematic review of methods to estimate colorectal cancer incidence using population-based cancer registries.BMC medical research methodology · 2022Pooled it
- Incidence and Risk Factors of Colorectal Cancer in the Iranian Population: a Systematic Review.Journal of gastrointestinal cancer · 2021Pooled it
- Determining the Survival Rate of Colorectal Cancer in Iran: A Systematic Review and Meta-AnalysisAsian Pacific journal of cancer prevention : APJCP · 2018Pooled it
- Time trend and geographical distribution of colorectal cancer incidence before and after COVID-19 pandemic in southern Iran: an interrupted time series analysis.Gastroenterology and hepatology from bed to bench · 2026Article
- Spatiotemporal Mapping of Colorectal and Gastric Cancer Incidence in Hamadan Province, Western Iran (2010-2019).Journal of research in health sciences · 2025Article
- Association betweenIranian journal of public health · 2025Review
- The 13-Year Trend of Colorectal Cancer in Isfahan, Iran.International journal of preventive medicine · 2025Article
- Heterogeneous expression of long noncoding RNA RP11-109D20.2: Insights into regulatory gene expression roles in colon cancer.Iranian journal of basic medical sciences · 2025Article
- Colorectal Cancer Incidence in Iran Based on Sex, Age, and Geographical Regions: A Study of 2014-2017 and Projected Rates to 2025.Archives of Iranian medicine · 2024Article
- Incidence of colorectal cancer in Iran: A systematic review and meta-analysis.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2024Review
- Determinants of survival and recurrence in patients with stage I colorectal cancer.Frontiers in surgery · 2024Article
- Trend of the polyp and adenoma detection rate by sex and age in asymptomatic average-risk and high-risk individuals undergoing screening colonoscopy, 2012-2019.Preventive medicine reports · 2023Article
- Geographical Distribution of Colorectal Cancer in Southwestern Iran Between Years 2011 and 2019.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023Article
- Article
- A joinpoint and age-period-cohort analysis of ocular cancer secular trends in Iran from 2004 to 2016.Scientific reports · 2023Article
- Enhanced anticancer potency with reduced nephrotoxicity of newly synthesized platin-based complexes compared with cisplatin.Scientific reports · 2022Article
- Serum level and tumor tissue expression of Ribonucleotide-diphosphate Reductase subunit M2 B: a potential biomarker for colorectal cancer.Molecular biology reports · 2022Article
- Diet-dependent acid load and the risk of colorectal cancer and adenoma: a case-control study.Public health nutrition · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesColorectal cancer (CRC) is the third most common cancer and the fourth most common cause of cancer death in the world. The aim of this study was to investigate the provincial distribution of the incidence of CRC across Iran.
methodsThis epidemiologic study used data from the National Cancer Registry of Iran and the Center for Disease Control and Prevention of the Ministry of Health and Medical Education of Iran. The average annual age-standardized rate (ASR) for the incidence of CRC was calculated for each province.
resultsWe found that adenocarcinoma (not otherwise specified) was the most common histological subtype of CRC in males and females, accounting for 81.91 and 81.95% of CRC cases, respectively. Signet ring cell carcinoma was the least prevalent subtype of CRC in males and females and accounted for 1.5 and 0.94% of CRC cases, respectively. In patients aged 45 years or older, there was a steady upward trend in the incidence of CRC, and the highest ASR of CRC incidence among both males and females was in the age group of 80-84 years, with an ASR of 144.69 per 100,000 person-years for males and 119.18 per 100,000 person-years for females. The highest incidence rates of CRC in Iran were found in the central, northern, and western provinces. Provinces in the southeast of Iran had the lowest incidence rates of CRC.
conclusionsWide geographical variation was found in the incidence of CRC across the 31 provinces of Iran. These variations must be considered for prevention and control programs for CRC, as well as for resource allocation purposes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.